Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL287351 | 0.84 | ALDH1A1 (0.51) | KMT2AMEN1ALDH1A1KDM4EGAA | |
| SCHEMBL287096 | 0.78 | ALDH1A1 (0.53) | KMT2AMEN1TSHRLMNAALDH1A1 | |
| SCHEMBL286751 | 0.78 | HTT (0.32) | KMT2AMEN1POLBALDH1A1KDM4E | |
| SCHEMBL287107 | 0.74 | LMNA (0.43) | KMT2AMEN1TSHRLMNAPOLB | |
| SCHEMBL287111 | 0.72 | HTT (0.37) | KMT2AMEN1POLBALDH1A1KDM4E | |
| SCHEMBL279616 | 0.72 | RAB9A (0.49) | KMT2AMEN1ALDH1A1KDM4ERAB9A | |
| SCHEMBL287364 | 0.71 | ALDH1A1 (0.51) | KMT2AMEN1TSHRLMNAALDH1A1 | |
| SCHEMBL279886 | 0.70 | ALDH1A1 (0.42) | KMT2AMEN1LMNAPOLBALDH1A1 | |
| SCHEMBL660456 | 0.70 | ALDH1A1 (0.55) | KMT2AMEN1LMNAPOLBALDH1A1 | |
| SCHEMBL661997 | 0.69 | ALDH1A1 (0.49) | KMT2AMEN1ALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DUTT CHAITANYA (IN) | 2012-02-23 | — | — | US | claimed |
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DUTT CHAITANYA (IN) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | AGER, REN, AGT | KMT2A 4512/4885MEN1 1455/4885TSHR 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.